# AEON Biopharma, Inc. (AEON)

> AEON Biopharma, Inc. (AEON) trades at $0.1398 (+5.03%) as of 5:51:02 AM EST on Nov 20, 2026, -44.59% over the past month. Market cap is $11.2M, with 6.4 days to cover in short interest.

Canonical: https://massive.com/quote/aeon
Data as of: 2026-11-20T10:51:02.795Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$0.1398** +0.01 (+5.03%)
As of 5:51:02 AM EST on Nov 20, 2026 · 15-minute delayed
NYSE American · usd

## Stock performance

How AEON Biopharma, Inc. (AEON) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +7.08% |
| 1W | -16.13% |
| 1M | -44.59% |
| YTD | -87.90% |
| 1Y | -83.96% |
| 52-wk range | $0.11 – $1.45 |

From daily closes through Nov 19, 2026.

## Key statistics

Today's trading snapshot for AEON: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | — |
| Open | — |
| Prev close | $0.13 |
| Volume | 34.72K |
| Market cap | $11.2M |
| Shares out | 71.52M |

## Valuation and profitability ratios

Valuation and profitability ratios for AEON Biopharma, Inc.: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 4.58 |
| P/FCF | — |
| ROE | -1995.8% |
| ROA | -337.0% |
| Debt/Equity | 1.21 |
| Div yield | 0.00% |

As of Nov 19, 2026

## Insider trading

[AEON Biopharma, Inc. (AEON) insider trading](https://massive.com/quote/aeon/insider-trading.md): open-market Form 4 buys and sells by AEON Biopharma, Inc. insiders over the last 12 months.

## 8-K filings

Material corporate events AEON Biopharma, Inc. has disclosed to the SEC on Form 8-K.

- Nov 16, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 16, 2026, AEON Biopharma, Inc. (the "Company" or "AEON") announced financial results for the third quarter ended September 30, 2026.”
- Nov 3, 2026 · [Regulatory decision](https://massive.com/quote/sec-filings/8-k/regulatory-decisions.md)
  “On September 30, 2026, the Company publicly announced that it had received Type 2b meeting minutes from the U.S. Food and Drug Administration that did not preclude advancement of ABP-450 toward a Biologics License Application under the Section 351(k) biosimilar pathway, thereby triggering the accelerated expiration of the Two-Year Warrants in accordance with their terms.”
- Oct 23, 2026 · Investor presentation
  “On October 23, 2026, AEON Biopharma, Inc. made available in the investor relations section of its website a presentation (the "Corporate Presentation"), a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.”
- Sep 30, 2026 · [Regulatory decision](https://massive.com/quote/sec-filings/8-k/regulatory-decisions.md)
  “The FDA agreed in principle with the Company's proposed two-stage design for a comparative pharmacodynamic study using Compound Muscle Action Potential ("CMAP") measurement in the extensor digitorum brevis muscle, consisting of an initial dose-finding stage followed by a comparative pharmacodynamic evaluation. The FDA provided recommendations intended to strengthen the study's ability to demonstrate assay sensitivity.”
- Aug 3, 2026 · [Listing compliance regained](https://massive.com/quote/sec-filings/8-k/delisting-notices.md)
  “On August 3, 2026, the Company received a letter from NYSE Regulation confirming that the Company has regained compliance with the continued listing standards of NYSE American. The letter stated that the Company is in compliance with all of the NYSE American continued listing standards set forth in Part 10 of the NYSE American Company Guide.”

## Dividend history and stock splits

AEON Biopharma, Inc.'s recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 1-for-72 · Feb 26, 2025

## AEON short interest

How heavily AEON is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 6.4 |
| Short interest | 2.66M |
| Avg volume | 415.78K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## AEON news

The latest news and headlines about AEON Biopharma, Inc. (AEON).

- [Bitget Launchpool adds AEON (AEON) with 1.1M in Token Rewards](https://www.globenewswire.com/news-release/2026/07/27/3333428/0/en/Bitget-Launchpool-adds-AEON-AEON-with-1-1M-in-Token-Rewards.html) · GlobeNewswire Inc. · Jul 27, 2026 · positive sentiment
- [AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society](https://www.globenewswire.com/news-release/2026/06/04/3306620/0/en/AEON-Biopharma-to-Present-Data-Demonstrating-Structural-and-Functional-Comparability-of-ABP-450-to-BOTOX-at-the-68th-Annual-Scientific-Meeting-of-the-American-Headache-Society.html) · GlobeNewswire Inc. · Jun 4, 2026 · positive sentiment
- [AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711](https://www.globenewswire.com/news-release/2026/04/03/3268137/0/en/AEON-Biopharma-Reports-Inducement-Grants-Under-NYSE-American-LLC-Company-Guide-Section-711.html) · GlobeNewswire Inc. · Apr 3, 2026 · neutral sentiment
- [AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711](https://www.globenewswire.com/news-release/2025/12/19/3208775/0/en/AEON-Biopharma-Reports-Inducement-Grants-Under-NYSE-American-LLC-Company-Guide-Section-711.html) · GlobeNewswire Inc. · Dec 19, 2025 · neutral sentiment
- [Migraine Clinical Trial Pipeline Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space \| DelveInsight](https://www.globenewswire.com/news-release/2025/12/02/3198356/0/en/Migraine-Clinical-Trial-Pipeline-Expands-as-30-Companies-Driving-Innovation-in-Oncology-Therapeutics-Space-DelveInsight.html) · GlobeNewswire Inc. · Dec 2, 2025 · neutral sentiment

## About AEON Biopharma, Inc.

AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.

| Measure | Value |
| --- | --- |
| Exchange | NYSE American |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 8 |
| Listed | Jul 24, 2023 |

[Company website](https://www.aeonbiopharma.com)

## FAQ

### What is the AEON Biopharma, Inc. (AEON) stock price today?

AEON Biopharma, Inc. (AEON) is trading at $0.1398 (+5.03% on the day) as of 5:51:02 AM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is AEON Biopharma, Inc.?

AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications.

### What is the short interest in AEON?

As of Oct 30, 2026, AEON has 2.66M shares short and 6.4 days to cover.

### What exchange is AEON listed on?

AEON Biopharma, Inc. (AEON) trades on NYSE American in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time AEON quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=AEON`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [AEON Biopharma, Inc. (AEON) insider trading](https://massive.com/quote/aeon/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
